| Sapanisertib studied in …STUDIED_INderived45 of 45show fewer |
|---|
| → studied in | NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · 45 trials list this drug (10 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06811116Phase 1/Phase 2 · recruiting Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial · 45 trials list this drug (10 active) | — | — | Hepatocellular Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02142803Phase 1 · active not recruiting TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors · 45 trials list this drug (10 active) | — | — | Solid Neoplasm,Primary Peritoneal Carcinoma,Adult Glioblastoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03047213Phase 2 · active not recruiting Sapanisertib in Treating Patients With Locally Advanced or Metastatic Bladder Cancer With TSC1 and/or TSC2 Mutations · 45 trials list this drug (10 active) | — | — | Transitional Cell Carcinoma,Bladder Neoplasm,Urothelial Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT07558733Phase 1/Phase 2 · recruiting Sapanisertib and Serabelisib (PIKTOR) in Various Combinations in Patients With HR+/HER2- Advanced/Metastatic Breast Cancer · 45 trials list this drug (10 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02503722Phase 1 · active not recruiting Testing the Combination of MLN0128 (TAK-228) and AZD9291 in Advanced EGFR (Epidermal Growth Factor Receptor) Mutation Positive Non-small Cell Lung Cancer · 45 trials list this drug (10 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04250545Phase 1 · active not recruiting Testing of the Anti Cancer Drugs CB-839 HCl (Telaglenastat) and MLN0128 (Sapanisertib) in Advanced Stage Non-small Cell Lung Cancer · 45 trials list this drug (10 active) | — | — | Malignant Lung Neoplasm,Leptomeningeal Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06385496Phase 2 · active not recruiting Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With mTOR Genetic Changes (MATCH - Subprotocol L) · 45 trials list this drug (10 active) | — | — | Lymphoma,Malignant Solid Neoplasm,Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06390865Phase 2 · active not recruiting Testing MLN0128 (TAK-228) as Potentially Targeted Treatment in Cancers With TSC1 or TSC2 Genetic Changes (MATCH - Subprotocol M) · 45 trials list this drug (10 active) | — | — | Lymphoma,Malignant Solid Neoplasm,Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04479306Phase 1 · completed Osimertinib in Combination With Alisertib or Sapanisertib for the Treatment of Osimertinib-Resistant EGFR Mutant Stage IIIB or IV Non-Small Cell Lung Cancer · 45 trials list this drug (10 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06463028Phase 2 · recruiting Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial Cancer · 45 trials list this drug (10 active) | — | — | Malignant Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02159989Phase 1 · completed Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery · 45 trials list this drug (10 active) | — | — | Solid Neoplasm,Malignant Solid Neoplasm,Ovarian Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05275673Phase 2 · terminated A Study of Sapanisertib in Relapsed/Refractory NFE2L2-Mutated and Wild-Type Squamous Non-Small Cell Lung Cancer · 45 trials list this drug (10 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02484430Phase 2 · completed Sapanisertib in Treating Patients With Relapsed and/or Refractory Acute Lymphoblastic Leukemia · 45 trials list this drug (10 active) | — | — | Adult Acute Lymphoblastic Leukemia,B Acute Lymphoblastic Leukemia,T Acute Lymphoblastic Leukemia+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03154294Phase 1 · completed Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors · 45 trials list this drug (10 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03097328Phase 2 · completed Study of TAK-228 In Patients With Previously Treated Metastatic Renal Cell Carcinoma · 45 trials list this drug (10 active) | — | — | Renal Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02133183Phase 1 · terminated Sapanisertib Before and After Surgery in Treating Patients With Recurrent Glioblastoma · 45 trials list this drug (10 active) | — | — | Glioblastoma,Gliosarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02244463Phase 1/Phase 2 · completed A Phase I/II Study of MLN0128 in Metastatic Anaplastic Thyroid Cancer and Incurably Poorly Differentiated or Radioidodine Refractory Differentiated Thyroid Cancer · 45 trials list this drug (10 active) | — | — | Thyroid Gland Neoplasm,Malignant Thyroid Gland Neoplasm,Thyroid Gland Anaplastic Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02893930Phase 2 · completed Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery · 45 trials list this drug (10 active) | — | — | Pancreatic Neuroendocrine Carcinoma,Pancreatic Neuroendocrine Tumor G1,Pancreatic Neuroendocrine Tumor G2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03017833Phase 1 · completed Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers · 45 trials list this drug (10 active) | — | — | Neoplasm,Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02049957Phase 2 · completed Safety and Efficacy Study of Sapanisertib in Combination With Exemestane or Fulvestrant in Postmenopausal Women With Estrogen Receptor Positive/Human Epidermal Growth Factor Receptor 2 Negative (ER+/HER2-) Metastatic Breast Cancer · 45 trials list this drug (10 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02756364Phase 2 · completed Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy · 45 trials list this drug (10 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03370302Phase 1 · terminated A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics (PK) of TAK-228 as Single Agent in Adult East Asian Participants With Advanced Nonhematological Malignancies · 45 trials list this drug (10 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02197572Phase 1 · completed Effect of Sapanisertib (MLN0128) on the QTc Interval in Participants With Advanced Solid Tumors · 45 trials list this drug (10 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02987959Phase 2 · terminated Study of TAK-228 (MLN0128) in Soft Tissue Sarcomas · 45 trials list this drug (10 active) | — | — | Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02601209Phase 1/Phase 2 · terminated Sapanisertib or Pazopanib Hydrochloride in Treating Patients With Locally Advanced or Metastatic Sarcoma · 45 trials list this drug (10 active) | — | — | Sarcoma,High Grade Sarcoma,Malignant Peripheral Nerve Sheath Tumor+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02575339Phase 1/Phase 2 · terminated MLN0128 Compared to Sorafenib in Advanced or Metastatic Hepatocellular Carcinoma · 45 trials list this drug (10 active) | — | — | Liver Neoplasm,Hepatocellular Carcinoma,Malignant Liver Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02719691Phase 1 · completed Phase I Study of MLN0128 and MLN8237 in Patients With Advanced Solid Tumors and Metastatic Triple-negative Breast Cancer · 45 trials list this drug (10 active) | — | — | Solid Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03430882Phase 1 · completed Sapanisertib, Carboplatin, and Paclitaxel in Treating Patients With Recurrent or Refractory Malignant Solid Tumors · 45 trials list this drug (10 active) | — | — | Malignant Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05022394Phase 1/Phase 2 · withdrawn Sapanisertib and Nivolumab for the Treatment of Stage I-IV Non-small Cell Lung Cancer in Patients Who Have Progressed on Prior PD-1/PD-L1 Inhibitor Therapy, I-OVERCOME Study · 45 trials list this drug (10 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02417701Phase 2 · completed Sapanisertib in Treating Patients With Stage IV or Recurrent Lung Cancer · 45 trials list this drug (10 active) | — | — | Lung Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02725268Phase 2 · completed A Study of Sapanisertib, Combination of Sapanisertib With MLN1117, Paclitaxel and Combination of Sapanisertib With Paclitaxel in Women With Endometrial Cancer · 45 trials list this drug (10 active) | — | — | Endometrial Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02724020Phase 2 · completed MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma · 45 trials list this drug (10 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02988986Phase 2 · completed TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer · 45 trials list this drug (10 active) | — | — | Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02514824Phase 1/Phase 2 · completed MLN0128 in Recurrent/Metastatic Merkel Cell Carcinoma · 45 trials list this drug (10 active) | — | — | Merkel Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04267913Phase 2 · withdrawn Testing of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel to the Usual Standard of Care for Advanced Squamous Cell Lung Cancer (A Lung-MAP Treatment Trial) · 45 trials list this drug (10 active) | — | — | Lung Carcinoma,Malignant Lung Neoplasm,Lung Squamous Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01058707Phase 1 · completed Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies · 45 trials list this drug (10 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02619669Phase 1 · withdrawn Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer · 45 trials list this drug (10 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02412722Phase 1 · completed A Safety, Tolerability, and Pharmacokinetics Study of MLN0128 as a Single Agent and in Combination With Paclitaxel in Adults With Advanced Nonhematologic Malignancies · 45 trials list this drug (10 active) | — | — | Non-Hematologic Malignancy | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02327169Phase 1 · completed A Study MLN2480 in Combination With MLN0128 or Alisertib, or Paclitaxel, or Cetuximab, or Irinotecan in Adult Participants With Advanced Nonhematologic Malignancies · 45 trials list this drug (10 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02091531Phase 2 · completed Dual mTOR Inhibitor MLN0128 in Advanced Castration-Resistant Prostate Cancer (CRPC) Patients · 45 trials list this drug (10 active) | — | — | Castration-Resistant Prostate Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01899053Phase 1 · completed A Safety and Pharmacokinetic Study of TAK-228 in Combination With TAK-117 in Adult Participants With Advanced Nonhematologic Malignancies · 45 trials list this drug (10 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01351350Phase 1 · completed Dose Escalation Study of MLN0128 in Combination With Paclitaxel, With/Without Trastuzumab, in Subjects With Advanced Solid Malignancies · 45 trials list this drug (10 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02812056Phase 1 · withdrawn Alisertib and TAK-228 in Participants With Human Papilloma Virus (HPV) Associated Malignancies · 45 trials list this drug (10 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01118689Phase 1 · completed Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia · 45 trials list this drug (10 active) | — | — | Multiple Myeloma,Waldenstrom Macroglobulinemia | 1 | Observed | clinicaltrials | graph → |